N/A N=40 An Analysis of Presentation and Outcome Following Treatment of Pancreatic Endocrine Neoplasms
Pancreatic Endocrine Neoplasms
Primary: Nonfunctioning and Malignant Pancreatic Endocrine Neoplasms — 28; 12; 22; 18 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=33 Endoscopic Ultrasound-guided Ethanol Injection of Pancreatic Cystic Neoplasms
Neoplasms, Cystic, Mucinous, and Serous
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 7; 16 participants
N/A N=341 Prevalence of Pancreatic Cysts During Routine Endoscopic Ultra Sound
Pancreatic Cysts
Primary: Prevalence of Pancreatic Cysts During Routine EUS — 46 participants found to have a cyst
N/A N=57 MRCP: A Reliable, Non Invasive Method for Staging Chronic Pancreatitis in Pediatrics
Healthy Volunteers
Primary: Total Secreted Fluid Volume as Measured by MR-PFT — 79 mL
N/A N=23 Secretin-Stimulated Magnetic Resonance Cholangiopancreatography (S-MRCP) in Pancreatic Patients
Pancreatic Cancer
Primary: S-MRCP and S-EUS Concordance
N/A N=340 Natural History and Management of Pancreatic Lesions in Von Hippel-Lindau Disease
Von Hippel-Lindau Disease
Primary: Number of Patients With Pancreatic Lesions Defined by Simple Cysts, Microcystic Adenomas, Neuroendocrine Tumors & Other Solid Lesions of the Pancreas Who Had Significant…
N/A N=66 In Vivo nCLE Study in the Pancreas With Endosonography of Cystic Tumors
Pancreatic Cysts
Primary: Sensitivity — 59 percentage of participants
N/A N=174 TOF-18F-FDG-PET/CT in Patients With Suspected Pancreatic Cancer
Pancreatic Cancer · Pancreatitis · IPMN
Primary: SUVmax (Maximal Standard Uptake Value) Measurement 30 and 90 Min p.i. (Post Injection) — 0.77; 0.78; 0.81; 0.8 SUVmax — p=0.78
N/A N=6 Radiopaque Hydrogel in Patients Undergoing Radiotherapy for Pancreatic Cancer
Pancreatic Adenocarcinoma
Primary: Number of Patients Where TraceIT Tissue Marker Placement Achieved — 6 Participants
N/A N=67 WallFlex Pancreatic Metal Stent for Pancreatic Duct Strictures
Chronic Pancreatitis
Primary: Pain Reduction — 12 Participants — p=0.999
Phase 4 N=15 Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI)
Pancreatic Cancer
Primary: To Determine the Sensitivity High Resolution Magnetic Resonance Imaging With Lymphotrophic Superparamagnetic Nanoparticles to Identify Small and Otherwise Undetectable…
N/A N=399 Pancreas Resection With and Without Drains
Pancreas Tumor · Pancreatitis
Primary: 60-day ≥ Grade II Complication Rate — 72; 76 Participants — p=0.804
N/A N=1 Stereotactic Radiation to Decrease Pancreatic Secretions
Pancreatic Fistulae
Primary: Decreased Secretions — 1 participants
Phase 3 N=121 Comparison of Two Needle Aspiration Techniques for Endoscopic Ultrasound-guided Fine Needle Aspiration (EUS-FNA) in Solid Pancreatic Lesions
Pancreatic Solid Lesions · Pancreatic Mass
Primary: Diagnostic Yield of Capillary Technique — 75.4 percentage of specimen
Phase 2 N=63 Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma
PDAC - Pancreatic Ductal Adenocarcinoma · FAP
Primary: Sensitivity of [68Ga]FAPI-46 PET Imaging to Detect PDAC, Using Histopathology as Truth Standard — 0.741 proportion of participants
Phase 3 N=168 Closed Suction Drainage and Natural Drainage of the Pancreatic Duct in Pancreaticojejunostomy
Pancreatic Fistula
Primary: Number of Patients With Pancreatic Fistula — 9; 8 participants
N/A N=168 Magnetic Resonance Imaging Study of Acute Pancreatitis
Acute Pancreatitis
Primary: The T2* Values in the Diagnosis of AP — 25.86; 21.06 ms — p=<0.01
N/A N=250 Evaluation of PCLs Using Three EUS-FNA Needles
Pancreatic Cystic Lesions
Primary: Volume of Aspirated Cyst Fluid as a Function of Estimated Maximal Volume — 78; 74; 73 percentage of cyst volume aspirated — p=0.84
N/A N=36 Respiratory-gated Stereotactic Body Radiation Therapy for Adenocarcinoma of the Pancreas or Periampullary Region
Pancreatic Neoplasms
Primary: Acute Toxicity Rates of Grade 3 or Greater Gastrointestinal and Hematologic Toxicities (as Raw Percentage) — 13.89; 0.00; 2.78; 0.00 percentage of participants
Phase 2 N=20 Intracystic Injection of NanoPac® in Subjects With Mucinous Cystic Pancreatic Neoplasms
Pancreatic Mucinous-Cystic Neoplasm
Primary: Number of Participants With Treatment Emergent Adverse Events (Safety and Tolerability) — 3; 3; 3; 9 Participants
Phase 3 N=200 Standardization of Surgery on the Pancreatic Cancer
Pancreatic Cancer
Primary: Survival — 37; 31 participants
N/A N=30 Early Increase in Blood Flow (EIBS) in the Duodenum in Patients With Pancreatic Cancer
Pancreatic Cancer
Primary: Deoxyhemoglobin Concentration (DHb) — .6968475; .3483283; .7021826; .4945491 alpha units — p=0.001
N/A N=1 Stereotactic Body Radiotherapy for Unresectable Pancreatic Cancer
Pancreatic Cancer
Primary: Local Control Rate — 1 Participants
N/A N=164 WallFlex Biliary Fully Covered (FC) Chronic Pancreatitis Study
Biliary Stricture
Primary: Number of Participants With Stricture Resolution — 47; 54 Participants — p=.008
N/A N=20 Evaluation of Pancreatic Pseudocyst Drainage With a Metal Stent
Pancreatic Pseudocysts
Primary: Technical Success of Endoscopic Ultrasound-guided Single-access Pseudocyst Drainage With a Fully Covered Self-expanding Metal Stent ; Anchored With a Double Pigtail…
Phase 2 N=48 Palliative Stereotactic Radiation for Pancreatic or Periampullary Adenocarcinoma
Pancreatic Cancer · Periampullary Adenocarcinoma
Primary: Late Gastrointestinal Toxicities — 13 Participants
Early Phase 1 N=23 Evaluation of 18 F-FP-DTBZ Pancreatic PET Scanning as a Tool to Measure Beta Cell Mass
Healthy Volunteers · Diabetes Mellitus, Type 1
Primary: Mean VMAT2 Functional Binding Capacity in the β Cells to 18 F-FP-DTBZ — 103; 38 unitless
N/A N=39 [11C]5-Hydroxy-tryptophan PET for Assessment of Islet Mass in Type 2 Diabetes
Type2 Diabetes
Primary: [11C]5-hydroxy-tryptophan Uptake in the Pancreas — 0.17; 0.21; 0.20; 0.23 % of injected dose — p=0.5875
Phase 2 N=11 Fat Malabsorption in Chronic Pancreatitis
Chronic Pancreatitis
Primary: Malabsorption Blood Test: Difference in Mean HA AUC Between Groups: Subjects With CP Compared to Healthy Subjects — 8.3; 17.7 mg*h/dL — p=<0.001
Phase 2 N=13 Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study
Advanced Pancreatic Carcinoma · Locally Advanced Pancreatic Carcinoma · Metastatic Pancreatic Carcinoma
Primary: Tumor Response — 5; 3 Participants